Principal Financial Group Inc. bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 45,205 shares of the company’s stock, valued at approximately $1,062,000. Principal Financial Group Inc. owned approximately 0.08% of Stoke Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Get Stoke Therapeutics alerts: ...

Financial Performance - Krystal Biotech reported earnings per share of $1.70, surpassing the estimated $1.62 [1][6] - The company achieved revenue of approximately $107.1 million, exceeding the estimated $105.1 million [1][6] - Revenue from VYJUVEK contributed to a total of $730.3 million since its U.S. launch [2][6] Liquidity and Financial Stability - The company ended the quarter with $955.9 million in cash and investments, indicating a strong liquidity position [3][6] - A current ratio of 10.14 suggests the company can easily cover its short-term liabilities [3] - The low debt-to-equity ratio of 0.0084 indicates minimal reliance on debt, providing financial stability [3] Valuation Metrics - The company's P/E ratio is 40.22, and the price-to-sales ratio is 21.47, reflecting investor confidence in its growth potential [4] - The enterprise value to sales ratio is 20.44, and the enterprise value to operating cash flow ratio is 43.30, highlighting a positive market outlook [4] - An earnings yield of 2.49% indicates a return on investment based on earnings [4] Strategic Focus and Future Goals - The company aims to support patients with dystrophic epidermolysis bullosa globally and plans to launch multiple products by 2030 [5] - Krystal Biotech intends to treat over 10,000 patients with rare diseases by 2030 [5] - Recent developments in cystic fibrosis research underscore the versatility of the company's approach [5]

Fourth Quarter and Full Year 2025 Financial and Operating Results February 17, 2026 © Copyright 2026 Krystal Biotech, Inc. All rights reserved. Forward Looking Statements and Disclosures This presentation and our discussion contain forward-looking statements that involve substantial risks and uncertainties. Any statements about future expectations, plans, and prospects for Krystal Biotech, Inc. (together with its subsidiaries, the "Company"), including but not limited to, statements about our U.S., Germany, ...

Core Viewpoint - Krystal Biotech, Inc. will report its fourth quarter and full year 2025 financial results on February 17, 2026, before U.S. markets open, and will host a conference call and webcast to discuss these results and provide a business update [1]. Company Overview - Krystal Biotech, Inc. is a fully integrated, commercial-stage global biotechnology company focused on discovering, developing, and commercializing genetic medicines for diseases with high unmet medical needs [3]. - The company's first commercial product, VYJUVEK, is the first-ever redosable gene therapy and the first genetic medicine approved in the U.S., Europe, and Japan for treating dystrophic epidermolysis bullosa [3]. - Krystal Biotech is advancing a robust pipeline of investigational genetic medicines and is headquartered in Pittsburgh, Pennsylvania [3].

Core Insights - Krystal Biotech, Inc. (NASDAQ:KRYS) is recognized as one of the top 10 growth stocks on NASDAQ for the next decade, with multiple analysts raising their price targets significantly, indicating strong future potential [1][3][5] Price Target Adjustments - Goldman Sachs raised its price target from $206 to $327, suggesting a 16.7% upside from current levels [1] - Clear Street increased its price target from $288 to $338, indicating a further 20.7% upside [3] - Bank of America adjusted its price target from $288 to $318, reflecting a 13.8% upside [5] Growth Programs - The company is focusing on short-term growth through three registrational programs: KB801, KB803, and KB407, with potential product launches expected around 2028 [1] - Ophthalmic programs are viewed as de-risked and scalable, leveraging the existing Vyjuvek commercial platform [2] Market Opportunities - KB407 is seen as a promising opportunity in cystic fibrosis, with long-term potential contingent on additional FEV1 data [2] - The neurotrophic keratitis market is a significant source of investor interest, particularly driven by KB801, which contributed to the upward revision of price targets [4] Company Overview - Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on developing genetic medicines for diseases with high unmet medical needs, with products including VYJUVEK, KB105, KB104, KB407, and KB707 [6]

Group 1 - Eli Lilly and Company has signed a $1.12 billion agreement with Seamless Therapeutics to develop treatments for hearing loss using gene-editing technology [2][4] - The partnership allows Lilly access to proprietary technology for designing programmable recombinases that can make precise changes to DNA linked to hearing loss [3] - Lilly will manage the program from early preclinical stages to commercialization, with the agreement including upfront payments and milestone-related payments [4] Group 2 - This deal is part of Lilly's broader strategy to expand its pipeline of genetic medicines across various diseases, moving beyond its successful weight-loss and diabetes drugs [5] - In the previous year, Lilly invested $1.3 billion to acquire Verve Therapeutics, enhancing its focus on gene-editing therapies for heart-related conditions [5] - Eli Lilly is a global pharmaceutical firm engaged in the discovery, development, manufacturing, marketing, and sale of medicines worldwide [6]

This presentation and our discussion contain forward-looking statements that involve substantial risks and uncertainties. Any statements about future expectations, plans, and prospects for Krystal Biotech, Inc. (together with its subsidiaries, the "Company"), including but not limited to, statements about our global VYJUVEK launch; selected preliminary 2025 unaudited results; our 2030 vision and the market potential of the product candidates that could be launched over the next four years; the development a ...

Core Insights - Krystal Biotech, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco, with CEO Krish S. Krishnan scheduled to present at 10:30 am ET [1] - A webcast of the presentation will be available on the Company's website starting at the same time [2] Company Overview - Krystal Biotech, Inc. is a fully integrated, commercial-stage global biotechnology company focused on genetic medicines for diseases with high unmet medical needs [3] - The Company's first commercial product, VYJUVEK, is the first-ever redosable gene therapy and the first genetic medicine approved in the US, Europe, and Japan for treating dystrophic epidermolysis bullosa [3] - The Company is advancing a robust pipeline of investigational genetic medicines across various fields, including respiratory, oncology, dermatology, ophthalmology, and aesthetics [3]

Core Insights - Oppenheimer & Co. Inc. has strengthened its Biotech Research Team by hiring Kostas Biliouris as Managing Director, enhancing its long-standing expertise in the biotech sector [1][3] - Biliouris brings extensive experience from BMO Capital Markets and Morgan Stanley, along with a Ph.D. in biochemical engineering, which will contribute to Oppenheimer's research capabilities in genetic medicines and biotech [2][3] - The firm aims to expand its research coverage in biotech, an area characterized by rapid innovation, to better serve its institutional and corporate clients [3][4] Company Overview - Oppenheimer & Co. Inc. is a subsidiary of Oppenheimer Holdings Inc., providing a comprehensive range of wealth management, securities brokerage, and investment banking services [4] - The healthcare franchise, including biotechnology, pharmaceuticals, and medical technology, has been a core area of expertise for Oppenheimer [3]

Core Insights - Passage Bio and PepGen are small-cap medical companies being compared based on various financial and operational metrics to determine which stock is more favorable [1][3][4]. Institutional Ownership - Passage Bio has 53.5% of its shares owned by institutional investors, while PepGen has 58.0% [1]. - Insider ownership stands at 5.0% for Passage Bio and 5.2% for PepGen, indicating a similar level of insider investment [1]. Analyst Ratings - Passage Bio has a consensus target price of $42.67, suggesting a potential upside of 363.26% [3][4]. - PepGen's consensus target price is $10.00, indicating a potential upside of 83.82% [3][4]. - Passage Bio has a stronger consensus rating with a score of 2.50 compared to PepGen's score of 2.33 [3]. Earnings and Valuation - Passage Bio reported a net income of -$64.77 million with an earnings per share (EPS) of -$14.40 [5]. - PepGen's net income is -$89.98 million with an EPS of -$2.82 [5]. - Passage Bio has a higher price-to-earnings ratio compared to PepGen, which is currently trading at a lower valuation [5]. Profitability - Passage Bio has a net margin of -102.09% and a return on equity of -52.97% [6]. - PepGen's net margin is -84.15% with a return on equity of -65.59% [6]. Risk & Volatility - Passage Bio has a beta of 1.86, indicating it is 86% more volatile than the S&P 500 [7]. - PepGen has a beta of 1.91, meaning it is 91% more volatile than the S&P 500 [7]. Summary - PepGen outperforms Passage Bio in 6 out of 11 factors compared [8].